Lexicon Pharmaceuticals Inc. (LXRX) Has Surged To A New High On Phase 3 Results

Lexicon Pharmaceuticals Inc. (LXRX) announced Friday morning that its Phase 3 clinical trial of sotagliflozin met its primary endpoint in patients with type 1 diabetes.

from RTT - Hot Stocks http://ift.tt/2cIh6OT
via IFTTT